Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03731637 · ClinicalTrials.gov registry record
A Study to Establish a New Onset Hyperglycemia and Diabetes Cohort
A clinical trial, sponsored by Fred Hutchinson Cancer Center.
- Terminated
- Registry status
- 2,269
- Enrollment target
NCT03731637: Clinical Trial study, sponsored by Fred Hutchinson Cancer Center.
NCT03731637 is a clinical trial that was terminated before completion, run by Fred Hutchinson Cancer Center. The registered enrollment target is 2,269 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03731637 was terminated before completion, sponsored by Fred Hutchinson Cancer Center.
- TERMINATED
- Registry status
- 2,269 participants
- Enrollment target
Study Summary
Create a large biobank of blood samples and data from subjects with new onset hyperglycemia and diabetes (NOD).
Primary Outcome
Enrolled subjects will be followed for three years to determine the 1-year, 2-year, 3-year incidence rates of PDAC in new-onset hyperglycemia and diabetes.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,269 participants |
| Start Date | 2018-10-15 |
| Est. Completion | 2025-03-31 |
Why NCT03731637 stopped before completion
NCT03731637 is an observational study that tracks outcomes without assigning an intervention. Its 2,269 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT03731637 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03731637 about?
NCT03731637 is a clinical study titled "A Study to Establish a New Onset Hyperglycemia and Diabetes Cohort". Create a large biobank of blood samples and data from subjects with new onset hyperglycemia and diabetes (NOD).
What is the current status of trial NCT03731637?
This trial is currently terminated. The enrollment target is 2,269 participants. The study started on 2018-10-15. Estimated completion is 2025-03-31.
Who is sponsoring clinical trial NCT03731637?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03968393 · 2,270 participants · Phase 4
Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress
- NCT04889872 · 2,250 participants · NA
PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR
- NCT06805513 · 2,250 participants · Phase 3
Actual Use Trial of Tadalafil 5 mg
- NCT05530343 · 2,298 participants · NA
Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI